Motley Fool Premium
  1. Stocks
    2. /
  2. Knight Therapeutics (TSX: GUD)
    3. /

TSX:GUD (Knight Therapeutics)

About GUD

Knight Therapeutics, Inc. engages in the business of acquiring, in licensing, out-licensing, marketing, and commercializing pharmaceuticals products. The firm also focuses on building a portfolio of innovative products through in-licensing or acquiring product rights. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montréal, Canada.
Financial Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Knight Therapeutics (TSX: GUD) Latest News

    Workers use a microscope to do medical research in a modern laboratory.
    Dividend Stocks

    2 Undervalued Canadian Stocks to Buy Now in May 2025

    | Amy Legate-Wolfe

    These undervalued Canadian stocks won't be down for long, especially for long-term investors.

    Read more »

    Doctor talking to a patient in the corridor of a hospital.
    Dividend Stocks

    Why I’d Consider These Top Healthcare Stocks for a $10,000 Long-Term Investment

    | Christopher Liew, CFA

    Three TSX stocks are suitable options for long-term investors seeking exposure to the healthcare sector.

    Read more »

    Stethoscope with dollar shaped cord
    Dividend Stocks

    Got $4,000? 4 Healthcare Stocks to Buy and Hold Forever

    | Amy Legate-Wolfe

    These healthcare stocks may not sound exciting, but the future growth opportunities certainly are.

    Read more »

    Nurse uses stethoscope to listen to a girl's heartbeat
    Tech Stocks

    3 Top Healthcare Sector Stocks for Canadian Investors in 2025

    | Aditya Raghunath

    Investing in TSX healthcare stocks such as Kneat.com can help Canadians generate outsized gains in 2025 and beyond.

    Read more »

    Workers use a microscope to do medical research in a modern laboratory.
    Dividend Stocks

    Got $4,000? 4 Healthcare Stocks to Buy and Hold Forever

    | Adam Othman

    Consider adding these four healthcare stocks to your portfolio if you have the capital to invest in the stock market…

    Read more »

    doctor uses telehealth
    Dividend Stocks

    Got $4,000? 4 Healthcare Stocks to Buy and Hold Forever

    | Amy Legate-Wolfe

    Healthcare stocks will always be a part of the market as essential investments, but these four look like strong long-term…

    Read more »

    Rocket lift off through the clouds
    Dividend Stocks

    3 TSX Stocks Ready to Explode in Value

    | Christopher Liew, CFA

    These stocks in rate-sensitive sectors could seriously break out after the rate cut.

    Read more »

    A doctor takes a patient's blood pressure in a clinical office.
    Dividend Stocks

    TSX Healthcare in April 2024: The Best Stocks to Buy Right Now

    | Christopher Liew, CFA

    TSX’s healthcare sector is not as popular as the heavyweight sectors, but it has three of the best stocks you…

    Read more »

    Stocks for Beginners

    2 Healthcare Stocks You Can Buy and Hold for the Next Decade

    | Amy Legate-Wolfe

    These two healthcare stocks are showing strong signs of growth for the next decade and are already improving by leaps…

    Read more »

    Dividend Stocks

    3 Growth Stocks to Invest $1,000 in Right Now

    | Christopher Liew, CFA

    Canadians can invest $1,000 in three growth stocks that are well-positioned to deliver far superior returns.

    Read more »

    Dividend Stocks

    2 Top Pharmaceutical Stocks to Buy on the TSX Today

    | Adam Othman

    Consider investing in these two TSX stocks if you want exposure to the pharmaceutical industry’s performance on the Canadian stock…

    Read more »

    Workers use a microscope to do medical research in a modern laboratory.
    Investing

    4 Biotech Stocks That Could Break Through the Market

    | Christopher Liew, CFA

    Four TSX biotech stocks could deliver outsized gains in 2023, as they are poised to break through the market soon.

    Read more »